By: Vasiliki Patsioura, MScAccess to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to the entire clinically eligible population. In the last five years, the market access landscape for cancer therapies has changed significantly with the addition of more treatment options, mainly immunotherapies. High-priced immune checkpoint inhibitors, a new class of anticancer drugs, have shown remarkable promise in the treatment of different cancer types such as melanoma, liver and lung cancers among others. The innovators of immune checkpoint inhibitors have often been asked to share the risk with governments for providing these high-cost therapies. In Italy, for example, offering discounts of up to 50% for cancer drugs is a common practice; governments have had to make essential policy changes, affecting the reimbursement of cancer drugs, to address the financial pressure for funding novel cancer therapies.